Owkin-Identified Biomarker-Defined Patient Subgroups In Phase 2 Trial Data Will Be Retrospectively Assessed By Servier

• Owkin completes first phase of project, identifying potential biomarker-defined patient subgroups  
• Servier will progress the project to the next phase by retrospectively evaluating Owkin’s findings in Phase 2 data, in line with Servier strategic orientation

Paris, France - 16 December 2025 - Owkin, an agentic AI company built to understand biology - today announces the next step in their ongoing collaboration with Servier Group. Owkin has used AI to identify new potentially sensitive subpopulations for a Servier asset currently in clinical development. Servier will now retrospectively assess the relevance of targeting these identified subpopulations using existing phase 2 clinical data.  If confirmed through additional analysis, these findings could contribute to a better understanding of patient populations relevant to future clinical development.

Thomas Clozel, CEO and Founder of Owkin said:

“We are thrilled that our partnership with Servier is moving to its next phase. Like Servier, our primary focus is scientific development, and this alliance is a further proof point of the pharmaceutical industry’s readiness to innovate and to advance medical breakthroughs using AI. Our cutting-edge tools can help our partners deliver better R&D results and better outcomes for patients with cancer and other serious diseases,”

Claude Bertrand, Executive Vice President, Research and Development, Servier said:

“At Servier, we are constantly exploring new ways to deepen our understanding of disease biology and to optimize the design of our clinical trials. Collaborations such as this one with Owkin illustrate how the integration of advanced AI can help us leverage patient’s data to generate data-driven hypotheses that could accelerate the development of innovative treatments for patients. We look forward to evaluating these insights and their potential scientific value within our clinical programs,”

Owkin’s results are enabled by the use of multimodal patient data gathered from cohorts accessed through its international network of academic partners. This multimodal data was then analyzed using Owkin’s proprietary AI tools within its Agentic Infrastructure for Biology, helping to identify potential patient subgroups for further investigation.